Morgan Stanley initiated coverage on Alkermes (NASDAQ: ALKS ) with an Equal-weight rating and a $21 price target. Morgan Stanley commented, "We have high regard for management, and see pipeline drug 5461 (depression) as intriguing. But we are cautious on commercialization prospects for 9070 (schizophrenia), and believe the